The transaction represents the final prepaid product-based payment due under the terms of its Hylenex licensing agreement, which provides Baxter with exclusive distribution rights. The payment has been booked as deferred revenue.
The transaction represents the final prepaid product-based payment due under the terms of its Hylenex licensing agreement, which provides Baxter with exclusive distribution rights. The payment has been booked as deferred revenue.